“Is curing patients a sustainable business model?” Goldman Sachs analysts ask [arstechnica.com]
Clearly, not. I mean why else haven't we seen a medical cure for obesity or #t2d #diabetes? Thankfully, I don't need big pharma's help for that one.
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask [arstechnica.com]
Clearly, not. I mean why else haven't we seen a medical cure for obesity or #t2d #diabetes? Thankfully, I don't need big pharma's help for that one.